QRxPharma hits on right dose

By Kate McDonald
Monday, 20 April, 2009

Sydney’s QRxPharma has completed a Phase III pilot study comparing the efficacy of its lead dual-opioid with its constituent parts.

The lead drug, MoxDuo IR, a combination of morphine and oxycodone, was found to reduce pain significantly more than its component parts, and had fewer side effects than the two drugs administered together.

QRxPharama is in Phase III trials with the immediate release version of MoxDuo and in earlier stage trials for controlled release and intravenous administration. It is also being compared against Percocet in joint replacement surgery.

Besides its analgesia work, the company is also developing a known compound to activate the chaperone protein Torsin for neurological diseases such as Parkinson’s, and has an anti-haemorrhagic and an anti-coagulant derived from venoms in pre-clinical trials.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd